2023年4月13日

2023年3月6日,印度孟買Fitterfly,從印度公司健康技術員,糖尿病和代謝健康領域的工作,最近展示了數據從其數字療法技術平台在第16屆國際先進技術與治療糖尿病會議(2023年ATTD)在柏林,德國。Fitterfly是為數不多的幾個印度醫療公司得到這個機會在過去的16年,從而把該公司的努力DTx的麵積在世界地圖。除了研究,今年Fitterfly是唯一的印度數字療法公司邀請參加科技展覽會上展覽世博會的創新部分。ATTD會議的目的是強調創新技術在糖尿病管理和治療。它彙集了開發人員患有糖尿病的新技術專業人員和管理者,研究人員,行業,創業公司,投資者,報銷當局和監管機構,以及糖尿病患者。博士在這個盛會,Arbinder信號(聯合創始人兼首席執行官)和Shailesh古普塔(聯合創始人兼首席運營官),提出了兩個研究論文強調Fitterfly糖尿病CGM數字的真實有效性治療計劃改善二型糖尿病患者的血糖控製和代謝參數。Fitterfly第一個演講專注於他們的數字療法解決方案如何能夠受益的參與者通過使用CGM-led行為改變,和個性化生活方式的改變在90天的計劃。研究數據包括145名患者14天,然後穿上CGM裝置獲得個性化的指導下11周根據他們的血糖反應。研究顯示10%的改善時間範圍內14天內(從66%到72%),從一個基線糖化血紅蛋白降低1% 8.1%的3個月。這也是伴隨著平均2.3公斤的體重。 UKPDS studies have shown that 1% reduction in HbA1c has significant benefits in terms of 14% reduction in all cause mortality, 30% reduction in retinopathy, kidney failure and strokes. Second study showed predictive insights for the need for CGM calibration and improved usage. This can be a transformational change as it will reduce the need for conventional finger prick tests for diabetes measurement. Speaking about this, Dr Arbinder Kumar Singal, CEO and CO-Founder, Fitterfly, said, "At Fitterfly, we have been on a mission to create a holistic and highly effective Diabetes Digital Therapeutics Program as a first line therapy for type 2 diabetes. It is a matter of great pride for us to make our outcomes presentation at ATTD and showcase the positive impact and potential of our Diabetes Digital Therapeutics (DTx) solution. More than 100 doctors from India participated in the research which we presented. During the conference, Fitterfly platform saw a lot of interest from doctors and visitors from across the globe and we believe we would be able to work with global stakeholders in the battle against diabetes." Fitterfly is championing an advanced approach to controlling diabetes with a slew of personalized programmes, by focusing on personalized glycemic response-based coaching. With 400 Mn people using smartphones, use of personalised technology can help Indians prevent, reverse and manage diabetes much better. About Fitterfly Fitterfly is a digital therapeutics start-up addressing metabolic health conditions such as diabetes, obesity, PCOS, hypertension and heart disease. Set up in 2016, the company has a team of more than 300 people spread across India and passionately working towards achieving best-in-class health outcomes for its members, employees, doctors and organisations. Fitterfly DTx programs have shown clinical benefits in terms of medication reduction, stress reduction, better control of disease conditions, enhanced sleep quality and productivity among members. The company has presented 50 research papers in international medical conferences and is trusted by 1000+ doctors in India. Fitterfly is well supported by its investors – Amazon, Fireside Ventures, Venture Catalysts and 9Unicorns. SOURCE Fitterfly